FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387447798> ?p ?o ?g. }

• W4387447798 abstract "Advanced bladder squamous cell carcinoma (aBSCC) is an uncommon form of urinary bladder malignancy when compared with the much higher urothelial carcinoma incidence. We studied the genomic alteration (GA) landscape in a series of aBSCC based on the association with human papilloma virus (HPV) to determine if differences in GA would be observed between the positive and negative groups.Using a hybrid capture-based FDA-approved CGP assay, a series of 171 aBSCC were sequenced to evaluate all classes of GA. Tumor mutational burden (TMB) was determined on up to 1.1 Mbp of sequenced DNA and microsatellite instability (MSI) was determined on up to 114 loci. Programmed cell death ligand -1 (PD-L1) expression was determined by IHC (Dako 22C3) with negative expression when PD-L1 was 0, lower expression of positivity set at 1 to 49%, and higher expression set at ≥50% expression.Overall, 11 (6.4%) of the aBSCC were found to harbor HPV sequences (10 HPV16 and 1 HPV 11). HPV+ status was identified slightly more often in women (NS) and in younger patients (P = 0.04); 2 female patients with aBSCC had a prior history of SCC including 1 anal SCC and 1 vaginal SCC. HPV+ aBSCC had fewer GA/tumor (P < 0.0001), more inactivating mutations in RB1 (P = 0.032), and fewer inactivating GA in CDKN2A (P < 0.0001), CDKN2B (P = 0.05), TERT promoter (P = 0.0004) and TP53 (P < 0.0001). GA in genes associated with urothelial carcinoma including FGFR2 and FGFR3 were similar in both HPV+ and HPV- aBSCC groups. MTAP loss (homozygous deletion) which has emerged as a biomarker for PRMT5 inhibitor-based clinical trials was not identified in any of the 11 HPV+ aBSCC cases, which was significantly lower than the 28% positive frequency of MTAP loss in the HPV- aBSCC group (P < 0.0001). MTOR and PIK3CA pathway GA were not significantly different in the 2 groups. Putative biomarkers associated with immunotherapy (IO) response, including MSI and TMB status, were also similar in the 2 groups. PD-L1 expression data was available for a subset of both HPV+ and HPV- cases and showed high frequencies of positive staining which was not different in the 2 groups.HPV+ aBSCC tends to occur more often in younger patients. As reported in other HPV-associated squamous cell carcinomas, HPV+ aBSCC demonstrates significantly reduced frequencies of inactivating mutations in cell cycle regulatory genes with similar GA in MTOR and PIK3CA pathways. The implication of HPV in the pathogenesis of bladder cancer remains unknown but warrants further exploration and clinical validation." @default.
• W4387447798 created "2023-10-10" @default.
• W4387447798 creator A5007596753 @default.
• W4387447798 creator A5007706410 @default.
• W4387447798 creator A5012877447 @default.
• W4387447798 creator A5015235928 @default.
• W4387447798 creator A5026717218 @default.
• W4387447798 creator A5027087424 @default.
• W4387447798 creator A5030533194 @default.
• W4387447798 creator A5031893418 @default.
• W4387447798 creator A5032268177 @default.
• W4387447798 creator A5033353421 @default.
• W4387447798 creator A5034005227 @default.
• W4387447798 creator A5053703940 @default.
• W4387447798 creator A5056054097 @default.
• W4387447798 creator A5067701996 @default.
• W4387447798 creator A5070206086 @default.
• W4387447798 creator A5079906541 @default.
• W4387447798 creator A5083331837 @default.
• W4387447798 creator A5088559019 @default.
• W4387447798 date "2023-10-01" @default.
• W4387447798 modified "2023-10-13" @default.
• W4387447798 title "HPV-positive clinically advanced squamous cell carcinoma of the urinary bladder (aBSCC): A comprehensive genomic profiling (CGP) study" @default.
• W4387447798 cites W1976204185 @default.
• W4387447798 cites W1981926367 @default.
• W4387447798 cites W1985585626 @default.
• W4387447798 cites W1991694011 @default.
• W4387447798 cites W2025318635 @default.
• W4387447798 cites W2063117613 @default.
• W4387447798 cites W2113727679 @default.
• W4387447798 cites W2130188603 @default.
• W4387447798 cites W2160981405 @default.
• W4387447798 cites W2287840388 @default.
• W4387447798 cites W2481823919 @default.
• W4387447798 cites W2511852120 @default.
• W4387447798 cites W2606495925 @default.
• W4387447798 cites W2731455584 @default.
• W4387447798 cites W2786268518 @default.
• W4387447798 cites W2889877312 @default.
• W4387447798 cites W2969333588 @default.
• W4387447798 cites W2982786587 @default.
• W4387447798 cites W3001262658 @default.
• W4387447798 cites W3003725892 @default.
• W4387447798 cites W3005400930 @default.
• W4387447798 cites W3043618518 @default.
• W4387447798 cites W3044762253 @default.
• W4387447798 cites W3111728930 @default.
• W4387447798 cites W3173203999 @default.
• W4387447798 cites W3175956679 @default.
• W4387447798 cites W36012210 @default.
• W4387447798 cites W4210575080 @default.
• W4387447798 cites W4282823078 @default.
• W4387447798 cites W4283795955 @default.
• W4387447798 cites W4286005450 @default.
• W4387447798 cites W4304843018 @default.
• W4387447798 cites W4323928748 @default.
• W4387447798 cites W4362623632 @default.
• W4387447798 doi "https://doi.org/10.1016/j.urolonc.2023.09.001" @default.
• W4387447798 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37821306" @default.
• W4387447798 hasPublicationYear "2023" @default.
• W4387447798 type Work @default.
• W4387447798 citedByCount "0" @default.
• W4387447798 crossrefType "journal-article" @default.
• W4387447798 hasAuthorship W4387447798A5007596753 @default.
• W4387447798 hasAuthorship W4387447798A5007706410 @default.
• W4387447798 hasAuthorship W4387447798A5012877447 @default.
• W4387447798 hasAuthorship W4387447798A5015235928 @default.
• W4387447798 hasAuthorship W4387447798A5026717218 @default.
• W4387447798 hasAuthorship W4387447798A5027087424 @default.
• W4387447798 hasAuthorship W4387447798A5030533194 @default.
• W4387447798 hasAuthorship W4387447798A5031893418 @default.
• W4387447798 hasAuthorship W4387447798A5032268177 @default.
• W4387447798 hasAuthorship W4387447798A5033353421 @default.
• W4387447798 hasAuthorship W4387447798A5034005227 @default.
• W4387447798 hasAuthorship W4387447798A5053703940 @default.
• W4387447798 hasAuthorship W4387447798A5056054097 @default.
• W4387447798 hasAuthorship W4387447798A5067701996 @default.
• W4387447798 hasAuthorship W4387447798A5070206086 @default.
• W4387447798 hasAuthorship W4387447798A5079906541 @default.
• W4387447798 hasAuthorship W4387447798A5083331837 @default.
• W4387447798 hasAuthorship W4387447798A5088559019 @default.
• W4387447798 hasBestOaLocation W43874477981 @default.
• W4387447798 hasConcept C104317684 @default.
• W4387447798 hasConcept C121608353 @default.
• W4387447798 hasConcept C126322002 @default.
• W4387447798 hasConcept C142724271 @default.
• W4387447798 hasConcept C143998085 @default.
• W4387447798 hasConcept C180754005 @default.
• W4387447798 hasConcept C2777546739 @default.
• W4387447798 hasConcept C2779399171 @default.
• W4387447798 hasConcept C2779762690 @default.
• W4387447798 hasConcept C2779767149 @default.
• W4387447798 hasConcept C2780265364 @default.
• W4387447798 hasConcept C502942594 @default.
• W4387447798 hasConcept C54355233 @default.
• W4387447798 hasConcept C61320498 @default.
• W4387447798 hasConcept C71924100 @default.
• W4387447798 hasConcept C86803240 @default.
• W4387447798 hasConceptScore W4387447798C104317684 @default.
• W4387447798 hasConceptScore W4387447798C121608353 @default.

• next